



INVITATION TO INVEST IN **PROSTATYPE GENOMICS AB**

SUBSCRIPTION PERIOD: 21 MAY-4 JUNE 2025

ADVERTISEMENT

IMPORTANT INFORMATION

This information teaser constitutes marketing and is not a prospectus within the meaning of Regulation (EU) 2017/1129 of the European Parliament and of the Council. The invitation to subscribe for securities in Prostatype Genomics AB ("Prostatype Genomics" or the "Company") is only made through the prospectus published in May 2025, which is available on Prostatype Genomics' website www.prostatypegenomics.com. Investors are advised to read the prospectus in its entirety before making an investment decision. This information brochure may not be distributed, published or publicised in or into the United States, Australia, Japan, Canada, New Zealand, South Africa, Hong Kong, Switzerland or Singapore. The Information Brochure may not be sent to persons in these countries or any other jurisdiction to which it is unlawful to deliver unit rights, BTUs, new shares or warrants, except in accordance with applicable law and provided that it does not require additional prospectuses, registration or other measures in addition to those required by Swedish law. Unless otherwise expressly stated in the prospectus, unit rights, BTUs, new shares or warrants may not be offered, sold, transferred or delivered, directly or indirectly, in or into any of these countries.

NAVIA
CORPORATE FINANCE



FREDRIK RICKMAN, CEO, COMMENTS

Prostate cancer is the most common cancer among men in Europe and the second most common globally. At the same time, it is one of the most complex diseases to make the right treatment decisions about. Many patients are overtreated – resulting in lifelong side effects – while others are undertreated and risk serious disease progression. This is where Prostatype Genomics makes a real difference.

Our company is based on over fifteen years of research at Karolinska Institutet, with the goal of developing a tool that helps doctors make better, more individualised and precise treatment decisions for prostate cancer. The result is Prostatype® – a patented, IVDR-approved genetic test that combines advanced molecular biology with AI-based data analysis. Our test utilises the biopsy material taken at the time of diagnosis and adds a whole new layer of information, without the need for the patient to undergo further procedures. It is a clear example of how precision medicine can improve both treatment outcomes and quality of life.



Over the past two years, we have established a focused commercialisation strategy where we build clinical acceptance through local validation studies in parallel with sales activities. Today, Prostatype® is commercially available with sales initiated in selected EMEA markets (Nordic countries, Spain and Italy and under validation in Taiwan). However, it is the US – the world's largest market for prognostic gene tests where Prostatype® became commercially available in 2024 – that is our main strategic focus. Here, we are awaiting a decision on Medicare approval for reimbursement, which opens up for broad reimbursement and faster commercial uptake in the US healthcare system.

With the product fully developed, a solid business plan for the US with attractive margins and growing market interest, we are in a crucial phase. The rights issue will allow us to finance our continued expansion and finalise the Medicare process in the US. With additional capital through warrants, we can also scale up our organisation to better take advantage of the potential offered by the market.

We are convinced that Prostatype® can become a new standard in prostate cancer diagnostics, and that the Company is well positioned to create significant value for patients, healthcare systems and our shareholders.

Fredrik Rickman – CEO, Prostatype Genomics AB

INVESTMENT HIGHLIGHTS



Patented and IVDR-approved gene technology for prostate cancer – Prostatype® is a prognostic gene test for diagnosed prostate cancer based on gene expression in primary embryonic cancer stem cells – a test that helps improve treatment decisions and thus reduces the risk of over- and under-treatment.



Strong clinical potential with global interest – Prostatype® addresses a widespread global need for better decision support in prostate cancer treatment and is used as a complement to existing clinical tools - creating the potential for a broad impact in healthcare.



Clear commercial focus and geographical expansion – The Company has initiated commercialization in Sweden, Spain, Italy and Taiwan, with a particular focus on the US where the Medicare approval process is at an advanced stage - a key for broad market penetration.



Solid business model with attractive margins and low development risk – The product is fully developed and ready for market in both the US and Europe, and the Company is now focusing on building sales and demonstrating recurring revenue rather than product development – reducing operational risk.



Breakthrough in the US market expected in the near future – Ongoing application for Medicare approval in the US paves the way for reimbursement and entry into the world's largest prostate cancer market - a breakthrough decision is expected in 2025.



INTRODUCTION TO PROSTATYPE GENOMICS

Prostatype Genomics is the result of over fifteen years of research in prostate cancer genomics. The company was founded in 2007 as a spin-off from Cancer Center Karolinska (Karolinska Institutet, Stockholm). The result was the development of the now IVDR approved and marketed product Prostatype® Test System. In addition to Europe, Prostatype® is also launched in the US and in clinical use. All regulatory and commercial requirements are thus already met for the US market as well.

Prostatype® is a patented genetic test for prostate cancer prognosis that has been developed to provide the additional information often required to select the optimal treatment strategy for each unique patient. The Prostatype® system identifies the genetic fingerprint of prostate cancer by measuring gene expression focusing on the embryonic cancer stem cell genes in the tissue sample (biopsy) already obtained at the time of patient diagnosis. In other words, Prostatype Genomics uses the patient's original biopsy, which means that the patient in question does not need to undergo additional tests to be able to diagnose the prostate cancer while increasing the precision of the treatment decision.

Prostatype® is intended to be used as a complement to the current clinical diagnostic and prognostic methods routinely used in healthcare. Prostatype® is patented and, in the opinion of the Board, is the only prostate cancer genetic test that focuses on measuring gene expression in embryonal prostate cancer stem cells in a format that allows independent hospitals to perform testing.

The test analyzes the expression of genes in cancer cells from prostate tissue and, in combination with advanced algorithms and data analysis, provides decision support for optimal treatment of individual patients once prostate cancer has been confirmed. Using artificial intelligence (AI) technology, the Prostatype Genomics gene test makes it possible to better predict prostate cancer and categorize the patient's condition into different risk types. In this way, the test can reduce the risk of over- or under-treatment, which in many cases leads to major inconvenience for the patient in the form of lifelong side effects such as impotence and incontinence.


The Prostatype Genomics Test System is a package consisting of the Prostatype® RTqPCR kit, patient databases and algorithms, the PWS (Prostatype Web System) and the associated P-score.

STRATEGY

Prostatype Genomics has initiated the commercialization of Prostatype® and is following a focused strategy to maximize the impact in selected markets in the most cost-effective way in order to achieve recurring sales revenues and prove the business model in different geographical markets. An important part in addition to the focused sales efforts is to simultaneously strengthen the scientific foundation through local validation studies, which is often a prerequisite for doctors and healthcare to adopt a new product. The US is the Company's main strategic focus, and in addition it operates in the selected EMEA markets of the Nordics with a focus on Sweden, Spain, Italy and Taiwan.

Over the past two years, the Company has systematically worked to map and evaluate different markets and approaches on the ground in different countries from a commercial perspective to identify whether the following criteria are met or can be met in the near future:

- Clinical acceptance for genetic testing in prostate cancer and confirmed clinical benefit, and
- Market acceptance via clinicians evaluating and starting to use Prostatype®



MOTIVE AND USE OF PROCEEDS

In order to more vigorously commercialize and market Prostatype Genomics' Prostatype® gene test in the United States, the Company is awaiting Medicare reimbursement approval. The Company's application was submitted as planned in September 2024 and since then answers to additional questions have been submitted. The timing of the approval is difficult for the Company to estimate as it is related to processes with authorities in the US. The company is working with Swedish and American lawyers in the matter and the assessment is that approval should reasonably be obtained during 2025. With Medicare approval in hand, the Board's assessment is that Prostatype Genomics will be well positioned to commercialize Prostatype® in the United States.

In order to finance the above-mentioned company development and repayment of the outstanding bridge loan and its interest, Prostatype Genomics is conducting a rights issue with a maximum issue volume of approximately SEK 27.3 million (before issue costs). Through the maximum funds raised through the rights issue (after issue costs), the Company intends to finance the activities listed below:

- Completion of US validation study and Medicare approval process
- Ongoing commercialization activities in the US and Europe, and strengthening of working capital and ongoing operational activities
- Repayment of bridge loan
- Payment of bridge loan interest and set-up fee

Through the funds provided to the Company through warrants of series TO5 (after issue costs), the Company intends to finance the following activities:

- Scale-up of commercialization and organization in the US and ongoing operational costs

In order to accommodate any oversubscription of the rights issue, the board of directors of the Company may resolve on an over-allotment option to issue additional units of up to approximately 15 percent of the total number of units that can be issued through the rights issue. The net proceeds from the over-allotment option are intended to be used for commercialization efforts in the United States.

In the event that the rights issue is not fully subscribed, Prostatype Genomics will prioritize activities focused on the United States. It is the Board's assessment that the net proceeds from a fully subscribed initial rights issue are sufficient to finance the Company's ongoing operations and plans up to and including Q4 2025, and if warrants of series TO5 are exercised, the Company will be financed for a longer period depending on the extent to which these are exercised and at what exercise price.

THE OFFER IN BRIEF

Subscription period: 21 May-4 June 2025.

Subscription price: SEK 4.00 SEK per unit, corresponding to SEK 1.00 per share. Warrants of series TO5 are issued free of charge.

Issue volume: initially up to approximately SEK 27.3 million before issue costs. Through the attached series TO5 warrants issued in the rights issue, the Company may receive an additional approximately SEK 30.8 million.

Pre-subscription and guarantee commitments: the rights issue is contractually secured to a total of approximately 81 percent (corresponding to approximately SEK 22.1 million) through pre-subscription commitments, bottom and top guarantee commitments.

Warrants of series TO5: one (1) warrant of series TO5 entitles the holder to subscribe for one (1) newly issued share in the Company and may be exercised during the period from 3 to 17 September 2025. The subscription price for TO5 shall amount to seventy (70) percent of the volume-weighted average price of the share according to the official price statistics on Nasdaq First North Growth Market during a period of twenty (20) trading days ending prior to the start of the exercise period. However, the subscription price shall be no less than SEK 0.10 and no more than SEK 1.50. The subscription price shall be rounded to the nearest whole öre. The Company will announce the subscription price on the day before the first day of the exercise period.

Please note that your bank or broker for administrative reasons may adopt a shorter exercise period than to 4 June 2025. For questions about your specific deadline, please contact your bank/broker.



TERMS FOR THE OFFERING

PREFERENTIAL RIGHT TO SUBSCRIBE

Those who on the record date of 19 May 2025 were registered as shareholders in the share register maintained by Euroclear on behalf of the Company have preferential rights to subscribe for new units in proportion to the number of shares held on the record date. For each existing share held on the record date, one (1) unit right will be received. The unit rights entitle the holder to subscribe for new units with preferential rights, whereby one (1) unit right entitles the holder to subscribe for one (1) new unit. One (1) unit consists of four (4) shares and three (3) warrants of series TO5.

ISSUE VOLUME

The offering comprises a maximum of 6,835,213 units (corresponding to a total of 27,340,852 shares and 20,505,639 attached, non-cash consideration warrants of series TO5). The total issue amount amounts to a maximum of approximately SEK 27.3 million before issue costs.

WARRANTS OF SERIES TO5

One (1) warrant of series TO5 entitles the holder to subscribe for one (1) newly issued share in the Company and may be exercised during the period from 3 September 2025 to 17 September 2025. Provided that the initial rights issue is fully subscribed and that all attached, non-cash consideration warrants of series TO5 are fully exercised, the share capital will increase by an additional SEK 2,050,563.90.

The subscription price for TO5 shall amount to seventy (70) percent of the volume-weighted average price of the share according to the official price statistics on Nasdaq First North Growth Market during a period of twenty (20) trading days ending prior to the start of the exercise period. However, the subscription price shall be no less than SEK 0.10 and no more than SEK 1.50. The subscription price shall be rounded to the nearest whole öre. The Company will announce the subscription price on the day before the first day of the exercise period.

The warrant will be subject to trading from the date the BTUs are converted in Euroclear's system until 15 September 2025 and will be traded in Swedish kronor. Full terms and conditions for warrants of series TO5 are available on the Company's website: www.prostatypegenomics.com.

SUBSCRIPTION PRICE

The subscription price is SEK 4.00 per unit, which means that the price per share is set at SEK 1.00. No commission will be charged.

SUBSCRIPTION PERIOD

Subscription for new units with the support of unit rights shall take place from 21 May 2025 to 4 June 2025. The Board of Directors of the Company reserves the right to extend the subscription period. Any extension will be announced by the Company through a press release no later than 4 June 2025.

TRADING IN UNIT RIGHTS

Trading of unit rights will take place on Nasdaq First North Growth Market from 21 May 2025 to 30 May 2025. Shareholders should contact their bank or other authorized intermediary to carry out the purchase and sale of unit rights. Unit rights acquired during the aforementioned trading period will grant the same right to subscribe for units during the subscription period as the unit rights that shareholders receive based on their holdings in the Company on the record date.

UNEXERCISED UNIT RIGHTS

Unit rights that are not sold by 30 May 2025 or exercised to subscribe for units by 4 June 2025 will be cancelled from all VP accounts without compensation. No separate notification will be sent regarding the cancellation of unit rights.

OVER-ALLOTMENT OPTION

In the event that the rights issue is oversubscribed, the Board, with the authorization granted by the Annual General Meeting on 15 May 2025, may decide to issue additional units under the same terms as the rights issue, up to a maximum of approximately 15 percent of the total number of units in the rights issue. When making the decision on the issuance, the Board will determine the allocation in accordance with the allocation principles used in the rights issue. The right to subscribe for units in the over-allotment offering will be granted to those who subscribe for units in the rights issue without receiving full allocation.

ISSUE REPORTING AND SUBSCRIPTION

Direct registered shareholders

Shareholders or representatives of shareholders who are registered with Euroclear on the record date of 19 May 2025 will receive a pre-printed issue statement with an attached payment slip. Information will be available on the Nordic Issuing website (www.nordic-issuing.se) as well as on the Company's website (www.prostatypegenomics.com). Those listed in the special register of pledgees and others, maintained separately from the share register, will not receive any information and will be notified separately. A VP

statement reflecting the registration of unit rights on shareholders' VP accounts will not be sent.

SUBSCRIPTION WITH SUPPORT OF PREFERENTIAL RIGHT

Subscription with the support of preferential rights must be made through simultaneous cash payment no later than 4 June 2025. Subscription through payment must be made either with the pre-printed payment slip attached to the issue statement, or by subscribing on the Nordic Issuing platform according to the following two options:

1. Issue Statement (pre-printed payment slip from Euroclear). If all unit rights received on the record date are to be used for subscription, only the pre-printed payment slip should be used as the basis for subscription through cash payment.
2. Subscription via Nordic Issuing with the support of unit rights.

If a different number of unit rights than those shown on the pre-printed issue statement is used for subscription, for example, if unit rights have been acquired or sold, the subscription with the support of unit rights must be made on the Nordic Issuing platform at <https://minasidor.nordic-issuing.se/> and used as the basis for subscription through cash payment. The shareholder must log in to the platform and specify the number of unit rights they wish to exercise, the number of units they wish to subscribe for, and the amount to be paid. The registration is binding.

NOMINEE REGISTERED SHAREHOLDERS

Shareholders whose shares in the Company are held in custody by a bank or other custodian will not receive an issue statement. Subscription and payment must instead be made in accordance with the instructions from the respective bank or custodian. Please note that when exercising unit rights through a bank or custodian, this should be done early in the subscription period, as each bank/custodian may set different deadlines for the last day of subscription.

SUBSCRIPTION WITHOUT SUPPORT OF PREFERENTIAL RIGHT

Subscription for units without preferential rights shall take place during the same period as the subscription for units with preferential rights, that is, from 21 May 2025. The Board of Directors of the Company reserves the right, under all circumstances, to extend the subscription period and the payment period. Such an extension shall be communicated no later than the last day of the subscription period and published by the Company.

Notification of subscription for units without preferential rights must be made on the Nordic Issuing platform at <https://minasidor.nordic-issuing.se/>.

For shareholders whose holdings are registered with a custodian, the subscription for units without preferential rights must be made to the respective custodian and in accordance with their instructions, or if the holding is registered with multiple custodians, with each of them. In order to invoke subsidiary preferential rights, the subscription must be made through the custodian, as otherwise, there is no way to identify a specific subscriber who has subscribed for units both with and without the support of unit rights.

Incomplete or incorrectly completed subscriptions may be disregarded. It is only allowed to submit a "Subscription without the support of unit rights." The subscription must be made no later than 4 June 2025. The registration is binding.

Please note that your bank or broker for administrative reasons may adopt a shorter exercise period than to 4 June 2025.

SUBSCRIPTION OVER EUR 15,000

If the subscription amounts to or exceeds EUR 15,000, an anti-money laundering form must be completed and submitted to Nordic Issuing in accordance with the Swedish Act (2017:630) on measures against money laundering and the financing of terrorism. Please note that Nordic Issuing cannot release securities, despite payment being received, until the anti-money laundering check is provided to Nordic Issuing.

ALLOCATION IN SUBSCRIPTION WITHOUT PREFERENTIAL RIGHT

In the event that not all units are subscribed with the support of unit rights, the Board, within the framework of the maximum amount of the rights issue, will decide on the allocation of units to others who have subscribed for units without the support of preferential rights. Such allocation will, in the first instance, be made to subscribers who have subscribed for units with the support of unit rights, regardless of whether the subscriber was a shareholder on the record date for the issue or not, and, in the case of oversubscription, on a pro-rata basis in relation to the number of units subscribed for with the support of unit rights.



In the second instance, allocation will be made to those who have subscribed for units without the support of unit rights, and, in the case of oversubscription, on a pro-rata basis in relation to the number of units subscribed for in the application, and, to the extent that allocation cannot be made on a pro-rata basis, by lottery.

In the third instance, allocation will be made to guarantors in accordance with the terms of the issued guarantee commitments.

NOTIFICATION REGARDING ALLOCATION OF UNITSSUBSCRIBED WITHOUT PREFERENTIAL RIGHT

Notification of any allocation of units subscribed without preferential rights will be provided by sending an allocation notice in the form of a settlement note via email. Settlement notes are expected to be sent out as soon as possible after the subscription period ends, and payment should be made according to the instructions on the settlement note, no later than four banking days thereafter. Please note that there is no option to deduct the amount from the specified account. If payment is not made on time, the units may be transferred to another party. If the sales price in such a transfer is lower than the price in the Offer, the person who originally received the allocation of these units may be liable for all or part of the difference. No notice will be sent to those who did not receive an allocation.

ANNOUNCEMENT OF OUTCOME OF THE RIGHTS ISSUE

The outcome of the rights issue is planned to be announced on 5 June 2025, or as soon as possible after the subscription period has ended. The Company will publish the outcome of the rights issue through a press release.

PAID SUBSCRIBED UNIT (BTU)

Subscription through payment will be registered with Euroclear as soon as this can be done, which normally means a few banking days after payment. After that, a directly registered subscriber will receive a VP statement confirming that the booked paid subscribed units (BTU) have been recorded on the subscriber's VP account. Subscribed units are recorded as BTU on the VP account until the rights issue is registered with the Swedish Companies Registration Office (Bolagsverket). Shareholders whose holdings are held in custody with a bank or custodian will receive information from their respective custodian.

TRADING IN BTU

Trading in BTU will take place on Nasdaq First North Growth Market from 21 May 2025 until the rights issue is registered with the Swedish Companies Registration Office (Bolagsverket). Subscribed units are booked as BTU on the subscriber's VP account or custody account until the rights issue is registered with Bolagsverket, which is expected to occur in mid-June 2025.

DELIVERY OF SHARES AND WARRANTS

As soon as the rights issue is registered with the Swedish Companies Registration Office (Bolagsverket), BTU will be converted into shares and warrants without special notification from Euroclear. Please note that the issue may be partially registered with Bolagsverket.

TRADING IN THE SHARE

The shares of the Company are listed on Nasdaq First North Growth Market. The shares are traded under the ticker symbol "PROGEN" and have the ISIN code SE0023261532. The new securities will be admitted to trading when the conversion of BTU into shares and warrants occurs.

DILUTION

Through the rights issue, the Company's share capital may initially increase by up to SEK 2,734,085.20 through the issuance of up to 27,340,852 shares, corresponding to approximately 80 percent of the votes and capital in the Company. The dilution is based on the number of shares issued after the completion of a fully subscribed rights issue. With the full utilization of the TOS warrants within the framework of the rights issue, the share capital may increase by an additional SEK 2,050,563.90, corresponding to an additional approximately 38 percent of the votes and capital in the Company.

SUBSCRIPTION RESULTING IN THE OBLIGATION TO REPORT INVESTMENT ACCORDING TO THE FDI ACT

The Act on the Review of Foreign Direct Investments (2023:560) (the "FDI Act") applies to the Company's operations. In the event that the subscription of units would result in an investor's holdings exceeding the thresholds of 10, 20, 30, 50, 65, or 90 percent of the votes in the Company, the investor is required to report their investment in accordance with the FDI Act. This reporting obligation does not apply if the investor subscribes for units with preferential rights in relation to the number of shares the investor holds on the record date, 19 May 2025.

MISCELLANEOUS

The Board of Directors of the Company does not have the right to cancel, withdraw, or temporarily suspend the Offer to subscribe for new shares in the Company in accordance with the terms in the prospectus. In the event that an excessive amount is paid by a subscriber for the subscribed units, Nordic Issuing will ensure that the excess amount is refunded. In such a case, Nordic Issuing will contact the subscriber for the details of a bank account to which the excess amount can be refunded. No interest will be paid on the excess amount. Subscription of new units is irrevocable, and the subscriber cannot cancel or modify the subscription of new units. An incomplete or incorrectly filled-out application/subscription may be disregarded. If the payment for the subscribed units is made late, is insufficient, or is paid incorrectly, the application for subscription may be disregarded, or the subscription may be made for a lower amount. Any paid amounts that are not utilized will be refunded. If multiple applications/subscriptions of the same category are submitted, only the application/subscription received last by Nordic Issuing will be considered. Late payments of amounts under SEK 100 will only be refunded upon request.

ISSUING AGENT

Nordic Issuing AB acts as issuing agent in connection with the rights issue.

For full terms and conditions, please see the prospectus at www.prostatypegenomics.com, published in May 2025.

